As for familial PD, the identification of monogenic causal mutations such as SNCA, PINK1, DJ1, VPS35, VPS13C has aided in the understanding of the disease pathophysiology and identification of potential therapeutic targets; yet, these account for merely 10% of PD cases [1–3]. This evidence concerns the gene SNCA and Parkinson disease.